Conclusion: PNPLA3 may function primarily in a lipogenic capacity and inhibition of PNPLA3 may be a novel therapeutic approach for treatment of nonalcoholic fatty liver disease-associated hepatic insulin resistance. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.